PDS Biotechnology's Upcoming Key Opinion Leader Event
PDS Biotechnology Corporation (Nasdaq: PDSB), an innovative leader in immunotherapy, is set to host a Key Opinion Leader (KOL) event aimed at addressing crucial developments in treating HPV16-positive head and neck squamous cell carcinoma (HNSCC). This event is pivotal as it will illuminate the pathology of this prevalent cancer and provide insights into the upcoming VERSATILE-003 Phase 3 clinical trial involving Versamune HPV combined with pembrolizumab.
Details of the Event
The KOL event is scheduled for Tuesday, December 17, at approximately 12 p.m. ET, providing a convenient time for healthcare professionals and stakeholders to engage with leading experts in the field. Attendees will have the unique opportunity to hear from esteemed panelists, including:
- Dr. Francis “Frank” Worden from the Rogel Cancer Center at the University of Michigan
- Dr. Kevin Harrington, a distinguished figure at The Institute of Cancer Research, UK
Expert Panel Insights
The event will be expertly moderated by Dr. Kirk Shepard, Chief Medical Officer at PDS Biotech. Dr. Worden has gained recognition as a leading authority in treating oropharyngeal cancers caused by HPV, boasting an impressive history of over 190 peer-reviewed publications and involvement in various clinical trials. His expertise will offer invaluable perspectives on recent advancements in HNSCC treatment and research.
Dr. Harrington, a respected figure in the realm of biological cancer therapies, has also made significant contributions to groundbreaking clinical trials, such as KEYNOTE-048, which led to FDA approvals for novel treatment regimens. His participation provides a comprehensive understanding of the latest therapeutic strategies involving pembrolizumab.
Registration and Webcast Information
The webinar format allows participants from diverse locations to connect and absorb critical information. Registration details for the event are straightforward, and stakeholders interested in the latest research and advancements in oncology are encouraged to participate in this enlightening session.
About PDS Biotechnology
PDS Biotechnology is at the forefront of immunotherapy, focusing on innovative approaches to harness the immune system against various cancers and infectious diseases. This commitment is evident in their development of the targeted immunotherapy Versamune, which is being tested alongside standard checkpoint inhibitors. The COMBINE-003 trial further explores its efficacy alongside PDS01ADC, an IL-12 fused antibody drug conjugate, offering a unique triple-combination treatment strategy.
As the company advances its clinical trials, it remains dedicated to transforming cancer care through innovative therapies. To learn more about their pioneering work, interested individuals can explore PDS Biotech’s official channels.
Frequently Asked Questions
What is the goal of the KOL event hosted by PDS Biotech?
The KOL event aims to discuss advancements in treating HPV16-positive head and neck cancers and share insights on upcoming clinical trials.
Who are the key speakers at the event?
Key speakers include Dr. Francis Worden and Dr. Kevin Harrington, both renowned experts in cancer research and treatment.
What is Versamune and its significance in cancer treatment?
Versamune is a targeted immunotherapy being developed by PDS Biotech to enhance the immune response against specific cancers, including HPV-related malignancies.
How can interested parties participate in the event?
Participants can register for the event online to join the webcast and engage with the experts.
What does PDS Biotechnology focus on in its clinical research?
PDS Biotech focuses on developing immunotherapies that enable the immune system to effectively target and kill cancer cells while also creating vaccines for infectious diseases.
